By: IPP Bureau
Last updated : September 21, 2026 5:06 pm
The partnership brings together capabilities spanning lipid excipients, shielding polymers, nanoformulation and cGMP manufacturing
ABITEC and Curapath have signed a strategic memorandum of understanding (MoU) aimed at expanding access to high-purity custom lipids, PEG-free shielding technologies and advanced lipid nanoparticle (LNP) formulation solutions.
The collaboration combines ABITEC’s lipid chemistry and manufacturing expertise with Curapath’s PEG-free shielding polymer technologies and cGMP manufacturing capabilities, giving drug developers greater flexibility in designing fit-for-purpose LNP delivery systems.
While PEG-lipids remain widely used in LNP formulations, alternative shielding approaches could offer advantages for certain repeat-dosing applications. Under the MoU, the companies will work to broaden formulation options for developers working on vaccines, cell therapies, genetic medicines and other advanced therapeutics.
“This collaboration directly addresses one of the key needs in LNP development: greater flexibility in lipid and shielding technologies,” said Donald Kelemen, Chief Scientific Officer of ABITEC. “By combining ABITEC’s high-purity custom lipids with Curapath’s PEG-free platform and manufacturing capabilities, we can help customers accelerate the successful development of next generation therapeutics and vaccines.”
The partnership brings together capabilities spanning lipid excipients, shielding polymers, nanoformulation and cGMP manufacturing, with the companies targeting developers of increasingly complex therapeutic modalities.
“We are excited to collaborate with ABITEC, a company with a long-standing reputation for excellence in lipid science and manufacturing,” said Víctor R. de la Rosa, Commercial Product Manager at Curapath.
“Drug developers today need integrated solutions to support complex therapeutic modalities. By combining our expertise in PEG-free shielding technologies, lipid excipients, nanoformulation, and cGMP manufacturing, we are expanding the toolbox available to innovators working across nucleic acid therapeutics, vaccines, cell therapies, biologics, and other next-generation medicines."